Cadrenal Therapeutics Stock (NASDAQ:CVKD)
Previous Close
$13.09
52W Range
$8.22 - $22.90
50D Avg
$12.08
200D Avg
$15.06
Market Cap
$27.12M
Avg Vol (3M)
$30.42K
Beta
0.98
Div Yield
-
CVKD Company Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.